Heartseed Inc. announced that it had completed administration to the first patient with severe heart failure caused by ischemic heart disease in the company-sponsored Phase I/II clinical trial of HS-005, which involves catheter delivery of iPS cell-derived cardiac spheroids into the myocardium. The Independent Safety Evaluation Committee has approved continuation based on 4-week data.
On 27 October 2026, Heartseed Inc. announced that it had completed administration of its HS-005 therapeutic program, which involves catheter delivery of iPS cell-derived cardiac spheroids into the myocardium, to the first patient with severe heart failure caused by ischemic heart disease. The procedure was conducted as part of the EMERALD study (jRCT2033250454).
The company said that the Independent Safety Evaluation Committee had approved continuation of the clinical trial based on data from 4 weeks after administration, and plans to proceed with enrollment of the second patient onward.